Aim To investigate and assess knowledge and attitudes of pharmacists and physicians towards generic drugs prescription in order to evaluate current trends, obstacles to prescribe/dispense generics and suggest possible improvements of rational and economic prescribing having in mind scarce public budgets for drugs. Methods A cross-sectional survey among 450 primary care physicians (prescribers) and pharmacists in four major cities in Bosnia and Herzegovina (Sarajevo, Banja Luka, Tuzla and Mostar) during the period between January and March 2016 was conducted. The survey (questionnaire) was developed and physicians’ and pharmacists’ perception was examined using the 5-point Likert scale. Descriptive statistics was used to examine respondents’ characteristics and their responses to survey questions. The respondents perception based on different characteristics was assessed using ordinal logistic regression. Results Generally, positive attitudes towards generic drugs were found. Majority of respondents, 392 (87.0%) considered generic drugs the same as originators and they could be mutually substituted. Physicians were more likely to prescribe branded drugs, 297 (66.6%), even 391 (86.8%) were aware of generic alternatives. Respondents believed that patients considered generic drugs less effective, 204 (45.4%), and 221 (49.0%) disapproved generic substitution. Conclusion Our findings suggest that further education and more information about benefits of generic drugs should be provided to key stakeholders including patients. Also, clearer generic drugs policies should be introduced in order to improve generic prescribing and potentially improve access and optimize pharmaceutical public expenditures.
Babar Z, Awaisu A. Evaluating community pharmacists’ perceptions and practices on generic medicines: a pilot study from Peninsular Malaysia. J Generic Med 2008:315–30.
2
Beecroft G. Generic drug policy in Australia: a community pharmacy perspective. Aust New Zealand Health Policy 2007:7.
3
Shrank W, Liberman J, Fischer M, Girdish C, Brennan T, Choudhry N. Physician perceptions about generic drugs. Ann Pharmacother 2011:31–8.
4
Paraponaris A, Verger P, Desquins B, Villani P, Bouvenot G, Rochaix L, et al. Delivering generics without regulatory incentives? Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names. Health Policy 2004:23–32.
5
Tsiantou V, Zavras D, Kousoulakou H, Geitona M, Kyriopoulos J. Generic medicines: Greek physicians’ perceptions and prescribing practices. J Clin Pharm Ther 2009:547–54.
6
Kersnik J, Peklar J. Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies. J Clin Pharm Ther 2006:577–83.
7
Toklu H, Dülger G, Hıdıroğlu S, Akici A, Yetim A, Gannemoğlu H, et al. Knowledge and attitudes of the pharmacists, prescribers and patients towards generic drug use in Istanbul -Turkey. Pharm Pract 2012:199–206.
8
Skinstad S. Norwegian general practitioners’ experiences with and attitudes towards generic substitution in pharmacies 2012.
9
Olsson E, Sporrong K, S. Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract 2012:377–83.
10
Theodorou M, Tsiantou V, Pavlakis A, Maniadakis N, Fragoulakis V, Pavi E, et al. Factors influencing prescribing behaviour of physicians in Greece and Cyprus: results from a questionnaire based survey. BMC Health Serv Res 2009:150–9.
11
Chuaa G, Hassali M, Shafie A, Awaisua A. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy 2010:229–35.
12
Gossell-Williams M. Generic substitutions: a 2005 survey of the acceptance and perceptions of physicians in Jamaica. West Indian Med J 2007:458–63.
13
Frisk P, Rydberg T, Carlsten A, Ekedah A. Patients’ experiences with generic substitution: a Swedish pharmacy survey. JPHSR 2011:9–15.
14
Kjoenniksen I, Lindbaek M, Granas A. Patients’ attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006:284–9.
15
Sakurai H, Itoh Y, Hashizume K, Yamauchi T, Youshimachi S, Sugiyama H, et al. Survey of patients attitudes toward generic drugs substitution in community pharmacies. Jpn J Drug Inform 2011:149–57.
16
Juricic Z, Jablan J, Grubesic J, R. Proceedings of the 1st International Congress of Controlled Release Society 2015.
17
Carifio J, Rocco J. Ten common misunderstandings, misconceptions, persistent myths and urban legends about Likert Scales and Likert Response Formats and their antidotes. Journal of Social Sciences 2007:106–16.
18
Tarik Čatić 1 , Lejla Avdagić 2 n.d.
19
Zaključci Neophodno je pružiti dodatnu edukaciju i više informacija donosiocima odluka o prednostima generičkih lijekova, uključujući i pacijente. Također, treba uvesti jasnije smjernice o propisivanju generičkih lijekova kako bi se unaprijedilo njihovo propisivanje, čime bi se potencijalno poboljšala dostupnost i optimizirala javna potrošnja za lijekove n.d.;(86).
20
Simoens S. Interchangeability of off-patent medicines: A pharmacoeconomic perspective. Expert Rev Pharmacoecon Outcomes Res 2008:519–21.
21
Health Insurance Fund of Federation of Bosnia and Herzegovina. Annual report 2015.
22
Health Insurance Fund of Republic of Srpska. Annual reports 2010-2015 15AD.
23
Čatić T. Differences in reimbursement prices and inequalities to access most commonly prescribed medicines in Bosnia and Herzegovina. Value in Health 2015:A527.
24
Čatić T, Rustempašić E, Martinović I, Kešo A. Domestic pharmaceutical manufacturer market share in Bosnia and Herzegovina in comparison to neighbouring countries. Pharmacia 2015:97–107.
25
Selmanovic K, Zec L, Vanis S, Zecevic N, Setkic L, Rasic M, et al. Utilisation analysis of antihypertensive drugs in Bosnia and Herzegovina for the time-period 2013-2015 2016:116–20.
26
Lee I, Bloor K, Hewitt C, Maynard A. International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry -a systematic review. J Health Serv Res Policy 2015:52–9.
27
Katz M, Scherger J, Conard S, Montejano L, Chang S. Healthcare costs associated with switching from brand to generic levothyroxine. Am Health Drug Benefits 2010:127–34.
28
Mcmanus P, Birkett D, Dudley J, Stevens A. Impact of the minimum pricing policy and introduction of brand (generic) substitution into the Pharmaceutical benefits scheme in Australia. Pharmacoepidemiol Drug Saf 2001:295–300.
29
Organisation for Economic Co-operation and Development. OECD Health Statistics 2015.
30
Hellerstein J. The importance of the physician in the generic versus trade-name prescription decision. Rand J Econ 1998:108–36.
31
Shrank W, Liberman J, Fischer M, Girdish C, Brennan T, Choudhry N. Physician perceptions about generic dDrugs. Ann Pharmacother 2011:31–8.
32
Karim S, Pillai G, Ziqubu-Page T, Cassimjee M, Morar M. Potential savings from generic prescribing and generic substitution in South Africa. Health Policy Plan 1996:198–205.
33
Kanavos P. Generic policies: rhetoric vs reality. Euro Observer The Health Policy Bulletin 2008:1–6.
34
Toverud E, Hartmann K, Håkonsen H. A systematic review of physicians’ and pharmacists’ perspectives on generic drug use: what are the global challenges? Appl Health Econ Health Policy 2015:35-S45.
35
Čatić T, Begović B. The attitudes of pharmacists and physicians in Bosnia and Herzegovina towards adverse drug reaction reporting. Journal of Health Sciences 2016:1–9.
36
Heikkila R, Mäntyselkä P, Hartikainen-Herranen K, Ahonen R. Customers’and physicians’ opinions of and experiences with generic substitution during the first year in Finland. Health Policy 2007:366–74.
37
Mcgettigan P, Mcmanus J, Shea O, Chan B, Feely R, J. Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: prescribers’ concerns. Ir Med J 1997:146–7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
